Zacks Investment Research upgraded shares of SINOVAC BIOTECH (SVA) from UNDERPERFORM to NEUTRAL on July 18, 2012, with a target price of $2.30.
Sonovac Biotech Ltd. specializes in the research, development, commercialization, and sales of human vaccines for infectious illnesses such as hepatitis A and hepatitis B, influenza, "SARS", and avian flu. Sinovac is one of the leading emerging biotechnology companies in China.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on SINOVAC BIOTECH (SVA),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment